TOMORROW - Macitentan for Children with Pulmonary Artery Hypertension - Clinical Trial

We are doing this study to learn how to slow down disease growth in children with pulmonary arterial hypertension with the medicine Macitentan compared to standard of care (SoC).

Pulmonary Artery Hypertension (PAH)

Children who:
- Are between the ages of 2-17 years old.
- Have had Pulmonary Artery Hypertension for less than or equal to 5 years.

If you decide that your child will be part of this study, your child:
- Will be randomly assigned (like flipping a coin) to get the study drug, Macitentan, or standard of care.
- Be involved in the study for about 6 years.
- Required to come in for the study visit every 3 months.
- Will have blood draw, echocardiogram, completing questionnaires.